Skip to main content

Table 1 Patient characteristics and biological parameters on the day of pharmacokinetic monitoring

From: Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Patient characteristicsGroup RBT 150 mg TPW (n = 9)Group RBT 300 mg TPW (n = 7)p
Age (years)36.3 ± 6.7034.7 ± 6.920.643
Sex
 Male6/92/70.131
 Female3/95/7 
Weight (kg)51 ± 11.8849.7 ± 8.800.832
Body mass index (BMI)18.0 ± 3.7417.1 ± 2,370.604
Dose of lopinavir (mg)/kg/12 h8.07 ± 1.418. 51 ± 1.44 
Dose of ritonavir (mg)/kg/12 h2.02 ± 0.352.13 ± 0.36 
Laboratory parameters
 Haemoglobin (g/dL)10.3 ± 3.589.8 ± 1.450.802
 Leucocytes (103/mL)4960 ± 30503900 ± 16430.554
 Neutrophils (103/mL)3890 ± 19353956 ± 2985 
 Lymphocytes (103/mL)1420 ± 8371375 ± 8010.937
 Monocytes (103/mL)260 ± 89225 ± 1890.722
 AST (U/L)61.8 ± 20.3148.2 ± 37.440.507
 ALT (U/L)49.4 ± 34.2830 ± 22.310.363
 Creatinine (µmol/L)102.2 ± 27.54106.1 ± 62.010.926
 Total cholesterol (mmol/L)162 ± 29.10104.3 ± 58.440.200
 HDL cholesterol (mmol/L)24.3 ± 10.2623 ± 9.890.894
 Amylasaemia (U/L)116.6 ± 18.0398 ± 56.780.616
 Total bilirubin (µmol/L)6.2 ± 2.709.2 ± 4.800.360
 Direct bilirubin (µmol/L)0.87 ± 1.022.75 ± 2.330.213
 Lymphocytes TCD4 (cells/µL)221.1 ± 154.75285.8 ± 175.390.446
Type of tuberculosis
 SPPT7/97/70.475
 SNPT2/90/7)
WHO HIV stage
 Stage 21/90/70.562
 Stage 38/97/7 
  1. TPW three times per week, h hour, AST aspartate aminotransferase, AST alanine transaminase, HDL high-density lipoprotein, SNPT smear-negative pulmonary tuberculosis, SPPT smear-positive pulmonary tuberculosis